Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.
Peng
Zhaohui
Z
Shenzhen SiBiono GeneTech, Shenzhen Hi-Tech Industrial Park (North), Shenzhen 518057, China. zhpeng@sibiono.com
D000256:Adenoviridae / Q000235:genetics; D002681:China; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D005260:Female; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D011786:Quality Control; D012109:Research Support as Topic / Q000639:trends; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*
D016159:Tumor Suppressor Protein p53